Evidence map›Paper›PMID 39818336›Full record

Trial reportJournal of affective disorders2025

Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder.

Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, Marina Belenky, Vasant R Marur, A John Rush, W Edward Craighead, Helen S Mayberg, Boadie W Dunlop, Bruce S Kristal and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sudeepa BhattacharyyaDepartment of Biological Sciences, Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, USA.
Siamak MahmoudianDehkordiDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
Matthew J SniatynskiDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Marina BelenkyDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Vasant R MarurDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
A John RushDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Duke-National University of Singapore, Singapore, Singapore.
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Helen S MaybergDepartment of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Bruce S KristalDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA; Duke Institute of Brain Sciences, Duke University, Durham, NC, USA. Electronic address: rima.kaddurahdaouk@duke.edu.
Mood Disorder Precision Medicine Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD

Indexed as

Cognitive Behavioral TherapyDuloxetine HydrochlorideEscitalopramMajor Depressive DisorderNeurotransmitter AgentsSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsAdultFemaleHumansIndolesMaleMetabolomicsMiddle AgedSerotoninSignal TransductionDuloxetine HydrochlorideEscitalopramIndolesNeurotransmitter AgentsSelective Serotonin Reuptake InhibitorsSerotoninSerotonin and Noradrenaline Reuptake InhibitorsTryptophanTyrosineCognitive-behavioral therapyGut microbial metabolitesMajor depressive disorderMetabolomicsSerotonin norepinephrine reuptake inhibitorSerotonin reuptake inhibitor

Identifiers

PMID39818336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.